# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-121580
Filing Date
2021-10-01
Accepted
2021-10-01 07:00:43
Documents
4
Period of Report
2021-10-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2128596-1_def14a.htm | DEF 14A | 580901
2 | GRAPHIC | sg_mahermasoud-bw.jpg | GRAPHIC | 14696
3 | GRAPHIC | tm2128596d1-pc_page1bw.jpg | GRAPHIC | 512107
4 | GRAPHIC | tm2128596d1-pc_page24c.jpg | GRAPHIC | 410100
| Complete submission text file | 0001104659-21-121580.txt |  | 1872650

Mailing Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878
Business Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40674 | Film No.: 211297067
SIC: 8731 Services-Commercial Physical & Biological Research